TROPION-Breast02: Expert Perspectives on Efficacy, Clinical Applicability, and Representation in Metastatic TNBC

In this segment, the expert panel discusses the clinical implications of TROPION-Breast02 and the potential role of datopotamab deruxtecan (Dato-DXd) in first-line treatment of metastatic triple-negative breast cancer (TNBC) when immunotherapy is not an option. The Guardians highlight the trial’s positive efficacy findings, including improvements in progression-free and overall survival, while noting that the control arm consisted primarily of taxane monotherapy and that regional overall survival findings warrant careful interpretation. The Avengers discuss the relevance of the results for patients with aggressive disease, including those who experience early recurrence after treatment in the early-stage setting. The panel also considers additional findings presented at ESMO 2026 from an exploratory subgroup analysis of patients with stable, asymptomatic central nervous system metastases, including CNS-specific progression-free survival and objective response outcomes. Experts discuss the need for further data to clarify intracranial disease control and interpret regional subgroup findings cautiously given the small patient numbers and exploratory nature of the analyses. The discussion concludes with concerns about the limited representation of Black patients in clinical trials, emphasizing the importance of improving representation to better understand treatment efficacy and tolerability across diverse patient populations.